Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 1,870 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Rheumatoid Arthritis, Healthy Volunteers
Interventions: CE 224,535; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Feeding Disorders, Feeding and Eating Disorders, Avoidant/Restrictive Food Intake Disorder
Interventions: Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care, Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Months to 6 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Gestational Diabetes, Pregnancy, Glucose Intolerance
Interventions: Gestational diabetes screening with fasting 3 hour 100 gm, Gestational diabetes screening with fasting 2 hour 75g; Diagnostic Test
Lead sponsor: Esa M Davis, MD MPH FAAFP; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 921 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colitis, Ulcerative
Interventions: SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Prader Willi Syndrome, Hypoglycemia
Interventions: Infants with Prader-Willi Syndrome; Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Months to 12 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV2 Infection
Interventions: Testing for SARS CoV2 Antigen and Antibody; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Neoplasms
Interventions: Nilotinib and Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05161704 or placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Liver Metastases
Interventions: [18-F]- FDG - PET, Tumor ablation (TA), PET/CT Scan; Diagnostic Test · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastrointestinal Stromal Tumors
Interventions: CGT9486, Pexidartinib, Sunitinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Sternal Wound Infection, Mediastinitis
Interventions: Rapid Sternal Closure System, Conventional wire closure; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Respiratory Rate Monitoring
Interventions: Physiological Monitoring with SpO₂ Sensors and Capnography; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 4 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diet Habit
Interventions: Healthy Default Kids' Beverage Policy; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 3,480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Research Triangle Park, North Carolina • Philadelphia, Pennsylvania

Conditions: Postprandial Inflammation
Interventions: HFHC meal, HFHC MEAL plus Fiber; Other · Dietary Supplement
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cerebral Edema, Diabetic Ketoacidosis
Interventions: 0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more

Conditions: Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions: Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glucose Metabolism Disorder
Interventions: Oral glucose tolerance test (OGTT), Diet soda containing aspartame only; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Peripheral Arterial Disease, Intermittent Claudication
Interventions: Home-based leg heat therapy; Device
Lead sponsor: Purdue University; Other
Eligibility: 60 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions: Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Avatrombopag maleate 40 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia
Interventions: Magstim Rapid 2 system triggering Magstim Super Rapid system; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

Evaluating Hunger Manipulation During Feeding Intervention

Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Hypoglycemia in Prader-Willi Syndrome

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Rapid Sternal Closure System (TALON)

Respiration From Pleth Validation

Evaluating a Healthy Restaurant Kids Meals Policy

Anti-inflammatory Effects of Fiber

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

WISE CVD - Continuation (WISE HFpEF)

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results